Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Ktx-1001, a potent, selective MMSET/NSD2 inhibitor, enhances immunomodulatory and immune-directed therapies in preclinical models of multiple myeloma

View Full Paper
Ask AI
Bookmark
Share

Authors

VGVicki GambleEFErin Flynt

Discussion

Loading...

Member takes

Overview

Preclinical findings show KTX-1001 enhances pomalidomide and daratumumab effectiveness in multiple myeloma, indicating a new therapeutic approach.

Key Points

  • The aim is to evaluate the synergistic effects of KTX-1001 with immunomodulatory therapies in multiple myeloma.
  • Treated MM cell lines with escalating KTX-1001 and combinations of pomalidomide and daratumumab.
  • Assessed cell viability using CellTiter-Glo and flow cytometry.
  • Evaluated synergy with Bliss scoring.
  • KTX-1001 plus pomalidomide significantly reduced cell viability in resistant H929-POMR cells.
  • Combination resulted in >90% cell viability reduction at low doses of KTX-1001 and pomalidomide.
  • Pre-treatment with KTX-1001 enhanced T-cell lysis and activation in co-culture assays with healthy PBMCs.

Cite This Study

Gamble et al. (2025) studied this question.

synapsesocial.com/papers/69362f714fa91c937236e1cahttps://doi.org/10.1182/blood-2025-7456
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1GT919, a novel IKZF3/1 molecular glue degrader: Phase 1 safety and preliminary efficacy in relapsed or refractory multiple myeloma (R/R MM)2025
  2. 2Enhancing immunotherapy efficacy in myeloma with a novel dual-action mitochondrial toxic peptide that overcomes resistance and induces immunogenic cell death.2025
  3. 3EZH2 inhibition synergizes with aiolos/ikaros degradation via coordinated chromatin remodeling and FoxO activation in multiple myeloma2025 · 2 citations
  4. 4IgG2a-formatted 4-1BB agonism combined with S100A9 inhibition enhances T cell activation and tumor control in a preclinical model of multiple myeloma2025
  5. 5Epigenetic reprogramming via EZH1/2 inhibition enhances T cell-mediated immunotherapies against multiple myeloma2025